In recent years, the mammalian target of rapamycin (mTOR) inhibitors, rapamycin, and its analogs (Figure 1) have become promising therapeutic drugs against cancer because of mTOR’s role in tumor progression. The gene discussed is MTOR; the disease is cancer.